自拟凉血消疕汤治疗寻常型银屑病临床观察及其作用机制研究
|
摘要
目的:
1.观察凉血消疕汤治疗寻常型银屑病的临床疗效及安全性。
2.通过体外传代培养人永生化角质形成细胞株(HaCaT),观察不同浓度凉血消疙汤含药血清对HaCaT细胞增殖、血管内皮生长因子(VEGF)表达的影响并探讨其治疗银屑病的作用机制。为凉血消疕汤在临床的广泛应用提供理论基础。
方法:
一.观察凉血消疕汤治疗寻常型银屑病的临床疗效
1病例来源2005年8月-2008年3月武汉市第一医院皮肤科银屑病专科门诊患者,临床诊断寻常型银屑病,皮损面积小于30%体表面积,就诊前一月未经口服中药治疗未接受免疫抑制剂治疗的患者46例。
2患者按随机数字表法分为2组,两组在年龄、性别、病程、严重程度上无显著性差异(P＞0.05),具有可比性。治疗组26例服用凉血消疕汤,每日一剂,分两次口服。对照组20例服用郁金银屑片,每日3次,每次4片。局部治疗二组均采用10%煤焦油软膏。每2周为1疗程,连续观察8周后根据银屑病皮损面积和严重度指数PASI评分系统,来评价临床疗效。同时监测患者血尿常规,肝肾功能,记录不良反应。
3观察结束后采用SPSS14.0软件系统对结果进行分析。
二.观察不同浓度凉血消疕汤含药血清对HaCaT细胞增殖及血管内皮生长因子(VEGF)表达的影响
1体外培养HaCaT细胞传至第三代备用。当细胞融合80%以上时,加入0.25%胰酶消化,37℃、5%CO_2培养箱中孵育5min,倒置显微镜下观察细胞形态,细胞变圆,细胞间连接中断,加入适量培养基终止消化,轻轻吹打瓶壁使细胞呈单细胞悬液,添加适量培养基吹打混匀,接种至96孔板备用。
2大鼠灌胃制备盐水,低、中、高剂量凉血消疙汤血清分别作用于HaCaT细胞。将24只大鼠随机分为4组,空白对照组(生理盐水),凉血消疕汤低、中、高剂量组(0.5g/ml、1g/ml、2g/ml),每组6只,雌雄各半。给药组,每天灌胃给药一次,连续7天;对照组,每天灌服等量生理盐水。具体灌胃剂量按照《中医科研设计与统计学》(湖南科学技术出版社48实验动物给药方法52中药血清药理学方法)计算。末次灌胃1h后取血,分离血清,-20℃冰箱保存备用。
3采用MTT法观察凉血消疙汤含药血清对细胞增殖影响。调整细胞数至2×10~4的密度接种于96孔板,细胞70%-80%融合后弃去原培养液,加入无血清的DMEM培养基培养4小时后去上清,加入各组受试品,在酶标仪上测OD值。
4运用ELIsA法检测上清液中VEGF的表达,调整细胞数至1×10~5接种于24孔板,细胞70%-80%融合后弃去原培养液加入各组受试品,培养24小时后取上清按照人VEGF ELISA试剂盒(深圳晶美)步骤操作。
结果:
一.临床观察
根据PASI评分下降比值,治疗组痊愈率7.69%,显效率57.69%,总显效率65.38%;对照组痊愈率5%,显效率30%,总显效率35%;治疗组总显效率高于对照组,经统计学分析差异有统计学意义(P＜0.05)。治疗前,治疗组患者PASI评分9.64±3.86,对照组PASI评分9.58±2.48。治疗后,治疗组患者PSAI评分4.23±3.55,对照组患者PASI评分5.48±3.83,两组患者治疗后总评分比较差异有显著统计学意义(P＜0.01),治疗组优于对照组。
二.实验研究
1.抑制细胞增殖:各实验组分别作用HaCaT细胞24小时后,HaCaT细胞组OD_(492)为0.961±0.028,TGF-α刺激HaCaT细胞组OD_(492)为1.163±0.073,生理盐水大鼠血清组OD_(492)值为1.098±0.067,低、中、高含药血清组OD_(492)值分别为0.908±0.041、0.914±0.096、0.553±0.159,TGF-α刺激空白组OD_(492)值明显高于空白组OD_(492)(P＜0.05)随药物浓度梯度的升高,各含药血清组细胞增殖活性逐渐降低,与盐水组比较差异有统计学意义(P＜0.05),各加药组组间比较,低剂量组与中剂量组比较差异无统计学意义(P＞0.05),高剂量组与盐水血清组,低、中剂量组比较差异均有显著统计学意义(P＜0.01)。
2.抑制VEGF分泌:各实验组分别作用HaCaT细胞24小时后,VEGF表达量HaCaT细胞组OD_(450)值为0.47 3±0.142,TGF-α刺激HaCaT细胞组OD_(450)值为1.007±0.261,生理盐水大鼠血清组OD_(450)值为1.500±0.041,低、中、高含药血清组OD_(450)值分别为1.185±0.133、0.964±0.403、0.33±0.067,TGF-α刺激HaCaT细胞组OD_(450)值与HaCaT细胞组OD_(450)值比较差异有显著统计学意义(P＜0.01),并且随着药物浓度梯度的升高,各含药血清组VEGF分泌量逐渐降低,与盐水组比较差异有显著统计学意义(P＜0.01),各加药组组间比较差异亦有显著统计学意义(P＜0.01)。经相关回归分析显示,VEGF表达量与呈高度负相关,r=-0.998,P＜0.01。提示以上各凉血消疕汤含药血清对HaCaT细胞VEGF分泌有明显抑制作用,且具有浓度效应关系。
结论:
1.凉血消疕汤对寻常型银屑病临床治疗作用显著,明显优于对照组。
2.凉血消疙汤含药血清能够抑制HaCaT细胞增殖,有效下调HaCaT细胞VEGF的分泌量,抑制VEGF表达,从而抑制血管新生,这可能是其临床治疗银屑病的药理作用机制之一。
Objective
1.To observe the clinic curative effect and safety of Liangxuexiaobi Decoction(LXXB) for psoriasis vulgaris.
2.To observe the cell proliferation and VEGF expression of HaCaT cells which are cultured in vitro and intervened by different concentration of Liangxuexiaobi Decoction. Discuss the effective therapy mechanism of traditional Chinese medicine in psoriasis vulgaris and provide scientific basis for asiaticoside application in clinic.
Methods
Ⅰclinical observation
1.A total of 46 psoriasis vulgaris sample patients who came from the psoriasis clinic in The NO.1 Hospital of Wuhan from August,2005 to March,2008 were observed according to the standards of psoriasis area below 30%of human's body surface area,and never accepted the therapy of traditional Chinese medicine or immunosuppressive one month before observed.
2.The patients were divided into 2 groups randomly.Two groups have no obvious differrences in age、sex and PASI(P＞0.05)has comparability.The treatment group includes 26 cases which are given Liangxuexiaobi Decoction,one dose for one day,taken at two times,while the comparison group includes 20 cases which are given Yujinyinxie PIece, three times one day,with 4 pieces each time.Take 10%coal tar ointment as the local treatment both groups.We set every two weeks as a treatment course.Then the clinic curative effects of the two groups are compared according to the PASI,after observing four treatment courses consecutively.Also blood analysis、urine analysis、Hepatic function and renal function is monitored and reactions are recorded.
3.Statistics:After the observation,we analyzed all the data by SPSS14.0.
ⅡExperiment
1.HaCaT cells were cultured in vitro in 10%DMEM culture medium.Digest HaCaT cell by 0.25%pancreas enzyme,37℃、5%CO_2,5min,after the cells were pasted with the wall of culture bottle 70%-80%.Observed the morphological change of HaCaT through the convert microscope,add appropriate culture medium to stop the digestion when the cells turn round and the cells junctions get interrupted,blow the wall of culture bottle until it becomes unicellular suspension,then inoculated to 96 hole board.
2.Rats are divided into groups to make serum contained Liangxuexiaopi Decoction by intragastral.Divided 24 rats into 4 groups:blank comparison group(physiological Saline group,liangxuexiaobi decoction groups(the end concentration is 0.5g/ml、1g/ml、2g/ml),every group contain 6,half is female and the other is male.The rats of the LXXBD groups were medicated once a day,continuing for 7 days.The rats of blank compareis- on groups(physiological saline group)were medicated equal physiological saline ever- yday.(《TCM Research Design & Statistics》Hunan science and technology publicshing house 48 the method of medication about experimental animals).Collect blood 1 hour after the last intragastral,distill the serum,store at -20℃refrigerator.
3.Obtain the proliferation level of the cell which is intervened by LXXBD using MTT. Inoculated cells to 96 holes board when density is 2×10~4.Discard the old culture medium when the cells were pasted with the wall of culture bottle 70%-80%,then keep the culture medium without FBS for 4 hours,check the OD_(492)by the enzyme marks board after adding different concentration medicine.
4.Inoculated the cells to 96 holes board when density is 1×10~5.Discard the old culture medium when the cells were pasted with the wall of culture bottle 70%-80%,add different concentration medicine,collect supernatant after 24 hours,Check the expression of VEGF by ELISA according to the approach of Human VEGF ELISA KIT from Jingmei.
Result:
一.clinical observation
According to the decline ratio of PASI,as for the treatment group,the convalesceng ate is 7.69%,the showing results rate is 57.69%,and the total showing results rate is 65.38%.While for the comparison group,the convalescing rate is 5%,showing results rate is 30%,and the total showing results rate is 35%.The treatment group total showing results rate is higher than the comparison group.The score of the treatment group is 9.64±3.86 while the score of the comparison group is 9.58±2.48 before accept treatment,we get the the score of the treatment group is 4.23±3.55 while the score of the comparison group is 5.48±3.83 at the end of the observation,there is obvious differences between the scores below(P＜0.01).
二.experiment
1.In the experiment of MTT,the OD_(492)value of blank control group is 0.961±0.028, the OD_(492)value of blank control group which is intervened by TGF-a is 1.163±0.073, the OD_(492)value of blind comparison group is 1.098±0.067,the OD492 value of different LXXBD groups sequentially are 0.908±0.041、0.914±0.096、0.553±0.159.We can see that the OD_(492)value of blank control group which is intervened by TGF-a is higher than the OD_(492)value of blank control group(P＜0.05).Following the rising of medicine concentration gradient,the cell proliferation activation gradually reduced,the cell proliferation levels of LXXBD groups are obviously lower than which is in HaCaT cell group(P＜0.05),and among LXXBD groups,there is no significance difference between the low concentration group and medium concentration group (P＞0.05).But it shows an obvious difference between high concentration group and blind comparison group or low concentration group or medium concentration group (P＜0.01).
2.From the result of ELISA,we can find that the VEGF expression of blank control group is 0.473±0.142,the value of blank control group which is intervened by TGF-a is 1.001±0.261,and the value of different concentration LXXBD sequentially are 1.185±0.133、0.964±0.403、0.33±0.067.There is significant difference between blank control group which is intervened by TGF-a and blank control group(P＜0.01).the VEGF expression of LXXBD groups are obviously lower than which is in physiological saline group(P＜0.01).It shows that following the rising of medicine concentration gradient,the VEGF expression gradually reduced,and among the LXXBD groups,the values of VEGF expression also has difference(P＜0.01).By Correlation analysis,the VEGF expression is highly negatively related to medicine concentration gradient,r=-0.998,P＜0.01.It shows that LXXBD can evidently suppress the VEGF expression of HaCaT cell.
Conclusion:
1.The LXXBD has evident clinic curative effect for psoriasis vulgaris,it is better than the comparing group obviously.
2.The serum with LXXBD could restrain the proliferation of HaCaT cell and has a good effect of reducing the VEGF secretion,bating the expression of VEGF,and controlling the angiogenesis,which might be an effective therapy mechanism for psoriasis vulgaris curing.
1.观察凉血消疕汤治疗寻常型银屑病的临床疗效及安全性。
2.通过体外传代培养人永生化角质形成细胞株(HaCaT),观察不同浓度凉血消疙汤含药血清对HaCaT细胞增殖、血管内皮生长因子(VEGF)表达的影响并探讨其治疗银屑病的作用机制。为凉血消疕汤在临床的广泛应用提供理论基础。
方法:
一.观察凉血消疕汤治疗寻常型银屑病的临床疗效
1病例来源2005年8月-2008年3月武汉市第一医院皮肤科银屑病专科门诊患者,临床诊断寻常型银屑病,皮损面积小于30%体表面积,就诊前一月未经口服中药治疗未接受免疫抑制剂治疗的患者46例。
2患者按随机数字表法分为2组,两组在年龄、性别、病程、严重程度上无显著性差异(P＞0.05),具有可比性。治疗组26例服用凉血消疕汤,每日一剂,分两次口服。对照组20例服用郁金银屑片,每日3次,每次4片。局部治疗二组均采用10%煤焦油软膏。每2周为1疗程,连续观察8周后根据银屑病皮损面积和严重度指数PASI评分系统,来评价临床疗效。同时监测患者血尿常规,肝肾功能,记录不良反应。
3观察结束后采用SPSS14.0软件系统对结果进行分析。
二.观察不同浓度凉血消疕汤含药血清对HaCaT细胞增殖及血管内皮生长因子(VEGF)表达的影响
1体外培养HaCaT细胞传至第三代备用。当细胞融合80%以上时,加入0.25%胰酶消化,37℃、5%CO_2培养箱中孵育5min,倒置显微镜下观察细胞形态,细胞变圆,细胞间连接中断,加入适量培养基终止消化,轻轻吹打瓶壁使细胞呈单细胞悬液,添加适量培养基吹打混匀,接种至96孔板备用。
2大鼠灌胃制备盐水,低、中、高剂量凉血消疙汤血清分别作用于HaCaT细胞。将24只大鼠随机分为4组,空白对照组(生理盐水),凉血消疕汤低、中、高剂量组(0.5g/ml、1g/ml、2g/ml),每组6只,雌雄各半。给药组,每天灌胃给药一次,连续7天;对照组,每天灌服等量生理盐水。具体灌胃剂量按照《中医科研设计与统计学》(湖南科学技术出版社48实验动物给药方法52中药血清药理学方法)计算。末次灌胃1h后取血,分离血清,-20℃冰箱保存备用。
3采用MTT法观察凉血消疙汤含药血清对细胞增殖影响。调整细胞数至2×10~4的密度接种于96孔板,细胞70%-80%融合后弃去原培养液,加入无血清的DMEM培养基培养4小时后去上清,加入各组受试品,在酶标仪上测OD值。
4运用ELIsA法检测上清液中VEGF的表达,调整细胞数至1×10~5接种于24孔板,细胞70%-80%融合后弃去原培养液加入各组受试品,培养24小时后取上清按照人VEGF ELISA试剂盒(深圳晶美)步骤操作。
结果:
一.临床观察
根据PASI评分下降比值,治疗组痊愈率7.69%,显效率57.69%,总显效率65.38%;对照组痊愈率5%,显效率30%,总显效率35%;治疗组总显效率高于对照组,经统计学分析差异有统计学意义(P＜0.05)。治疗前,治疗组患者PASI评分9.64±3.86,对照组PASI评分9.58±2.48。治疗后,治疗组患者PSAI评分4.23±3.55,对照组患者PASI评分5.48±3.83,两组患者治疗后总评分比较差异有显著统计学意义(P＜0.01),治疗组优于对照组。
二.实验研究
1.抑制细胞增殖:各实验组分别作用HaCaT细胞24小时后,HaCaT细胞组OD_(492)为0.961±0.028,TGF-α刺激HaCaT细胞组OD_(492)为1.163±0.073,生理盐水大鼠血清组OD_(492)值为1.098±0.067,低、中、高含药血清组OD_(492)值分别为0.908±0.041、0.914±0.096、0.553±0.159,TGF-α刺激空白组OD_(492)值明显高于空白组OD_(492)(P＜0.05)随药物浓度梯度的升高,各含药血清组细胞增殖活性逐渐降低,与盐水组比较差异有统计学意义(P＜0.05),各加药组组间比较,低剂量组与中剂量组比较差异无统计学意义(P＞0.05),高剂量组与盐水血清组,低、中剂量组比较差异均有显著统计学意义(P＜0.01)。
2.抑制VEGF分泌:各实验组分别作用HaCaT细胞24小时后,VEGF表达量HaCaT细胞组OD_(450)值为0.47 3±0.142,TGF-α刺激HaCaT细胞组OD_(450)值为1.007±0.261,生理盐水大鼠血清组OD_(450)值为1.500±0.041,低、中、高含药血清组OD_(450)值分别为1.185±0.133、0.964±0.403、0.33±0.067,TGF-α刺激HaCaT细胞组OD_(450)值与HaCaT细胞组OD_(450)值比较差异有显著统计学意义(P＜0.01),并且随着药物浓度梯度的升高,各含药血清组VEGF分泌量逐渐降低,与盐水组比较差异有显著统计学意义(P＜0.01),各加药组组间比较差异亦有显著统计学意义(P＜0.01)。经相关回归分析显示,VEGF表达量与呈高度负相关,r=-0.998,P＜0.01。提示以上各凉血消疕汤含药血清对HaCaT细胞VEGF分泌有明显抑制作用,且具有浓度效应关系。
结论:
1.凉血消疕汤对寻常型银屑病临床治疗作用显著,明显优于对照组。
2.凉血消疙汤含药血清能够抑制HaCaT细胞增殖,有效下调HaCaT细胞VEGF的分泌量,抑制VEGF表达,从而抑制血管新生,这可能是其临床治疗银屑病的药理作用机制之一。
Objective
1.To observe the clinic curative effect and safety of Liangxuexiaobi Decoction(LXXB) for psoriasis vulgaris.
2.To observe the cell proliferation and VEGF expression of HaCaT cells which are cultured in vitro and intervened by different concentration of Liangxuexiaobi Decoction. Discuss the effective therapy mechanism of traditional Chinese medicine in psoriasis vulgaris and provide scientific basis for asiaticoside application in clinic.
Methods
Ⅰclinical observation
1.A total of 46 psoriasis vulgaris sample patients who came from the psoriasis clinic in The NO.1 Hospital of Wuhan from August,2005 to March,2008 were observed according to the standards of psoriasis area below 30%of human's body surface area,and never accepted the therapy of traditional Chinese medicine or immunosuppressive one month before observed.
2.The patients were divided into 2 groups randomly.Two groups have no obvious differrences in age、sex and PASI(P＞0.05)has comparability.The treatment group includes 26 cases which are given Liangxuexiaobi Decoction,one dose for one day,taken at two times,while the comparison group includes 20 cases which are given Yujinyinxie PIece, three times one day,with 4 pieces each time.Take 10%coal tar ointment as the local treatment both groups.We set every two weeks as a treatment course.Then the clinic curative effects of the two groups are compared according to the PASI,after observing four treatment courses consecutively.Also blood analysis、urine analysis、Hepatic function and renal function is monitored and reactions are recorded.
3.Statistics:After the observation,we analyzed all the data by SPSS14.0.
ⅡExperiment
1.HaCaT cells were cultured in vitro in 10%DMEM culture medium.Digest HaCaT cell by 0.25%pancreas enzyme,37℃、5%CO_2,5min,after the cells were pasted with the wall of culture bottle 70%-80%.Observed the morphological change of HaCaT through the convert microscope,add appropriate culture medium to stop the digestion when the cells turn round and the cells junctions get interrupted,blow the wall of culture bottle until it becomes unicellular suspension,then inoculated to 96 hole board.
2.Rats are divided into groups to make serum contained Liangxuexiaopi Decoction by intragastral.Divided 24 rats into 4 groups:blank comparison group(physiological Saline group,liangxuexiaobi decoction groups(the end concentration is 0.5g/ml、1g/ml、2g/ml),every group contain 6,half is female and the other is male.The rats of the LXXBD groups were medicated once a day,continuing for 7 days.The rats of blank compareis- on groups(physiological saline group)were medicated equal physiological saline ever- yday.(《TCM Research Design & Statistics》Hunan science and technology publicshing house 48 the method of medication about experimental animals).Collect blood 1 hour after the last intragastral,distill the serum,store at -20℃refrigerator.
3.Obtain the proliferation level of the cell which is intervened by LXXBD using MTT. Inoculated cells to 96 holes board when density is 2×10~4.Discard the old culture medium when the cells were pasted with the wall of culture bottle 70%-80%,then keep the culture medium without FBS for 4 hours,check the OD_(492)by the enzyme marks board after adding different concentration medicine.
4.Inoculated the cells to 96 holes board when density is 1×10~5.Discard the old culture medium when the cells were pasted with the wall of culture bottle 70%-80%,add different concentration medicine,collect supernatant after 24 hours,Check the expression of VEGF by ELISA according to the approach of Human VEGF ELISA KIT from Jingmei.
Result:
一.clinical observation
According to the decline ratio of PASI,as for the treatment group,the convalesceng ate is 7.69%,the showing results rate is 57.69%,and the total showing results rate is 65.38%.While for the comparison group,the convalescing rate is 5%,showing results rate is 30%,and the total showing results rate is 35%.The treatment group total showing results rate is higher than the comparison group.The score of the treatment group is 9.64±3.86 while the score of the comparison group is 9.58±2.48 before accept treatment,we get the the score of the treatment group is 4.23±3.55 while the score of the comparison group is 5.48±3.83 at the end of the observation,there is obvious differences between the scores below(P＜0.01).
二.experiment
1.In the experiment of MTT,the OD_(492)value of blank control group is 0.961±0.028, the OD_(492)value of blank control group which is intervened by TGF-a is 1.163±0.073, the OD_(492)value of blind comparison group is 1.098±0.067,the OD492 value of different LXXBD groups sequentially are 0.908±0.041、0.914±0.096、0.553±0.159.We can see that the OD_(492)value of blank control group which is intervened by TGF-a is higher than the OD_(492)value of blank control group(P＜0.05).Following the rising of medicine concentration gradient,the cell proliferation activation gradually reduced,the cell proliferation levels of LXXBD groups are obviously lower than which is in HaCaT cell group(P＜0.05),and among LXXBD groups,there is no significance difference between the low concentration group and medium concentration group (P＞0.05).But it shows an obvious difference between high concentration group and blind comparison group or low concentration group or medium concentration group (P＜0.01).
2.From the result of ELISA,we can find that the VEGF expression of blank control group is 0.473±0.142,the value of blank control group which is intervened by TGF-a is 1.001±0.261,and the value of different concentration LXXBD sequentially are 1.185±0.133、0.964±0.403、0.33±0.067.There is significant difference between blank control group which is intervened by TGF-a and blank control group(P＜0.01).the VEGF expression of LXXBD groups are obviously lower than which is in physiological saline group(P＜0.01).It shows that following the rising of medicine concentration gradient,the VEGF expression gradually reduced,and among the LXXBD groups,the values of VEGF expression also has difference(P＜0.01).By Correlation analysis,the VEGF expression is highly negatively related to medicine concentration gradient,r=-0.998,P＜0.01.It shows that LXXBD can evidently suppress the VEGF expression of HaCaT cell.
Conclusion:
1.The LXXBD has evident clinic curative effect for psoriasis vulgaris,it is better than the comparing group obviously.
2.The serum with LXXBD could restrain the proliferation of HaCaT cell and has a good effect of reducing the VEGF secretion,bating the expression of VEGF,and controlling the angiogenesis,which might be an effective therapy mechanism for psoriasis vulgaris curing.
引文
[1]邵长庚.我国银屑病的流行和防治现状[J].中华皮肤科杂志,1996,29(2):75-76
[2]赵辩.临床皮肤病学[M],第3版,南京:江苏科学技术出版社,759
[3]陈积愫,郑敏.银屑病与血管生成因子[J].国外医学皮肤性病学分册,2000,26(1):13-16
[4]Jens Gille,Kerstin Reisinger,Bindhu Westphal-Varghese,et al.Decreased mRNA Stability as a Mechanism of Glucocorticoid-Mediated Inhibition of Vascular Endoth- elial Growth Factor Gene Expression by Cultured Keratinocytes[J].The journal of investigative dermatology.2001,117(6):1851-1857
[5]林熙然.隋代到清代中医医籍中有关银屑病的资料综述[J].中国中西医结合皮肤性病学杂志,2002,1(1):60-63
[6]孙捷,张虹亚.中医药治疗银屑病的研究进展[J].甘肃中医.2007,20(7):95-97
[7]北京中医医院.赵炳南临床经验集[M].北京:人民卫生出社,1997:227
[8]杜锡贤,范玉.寻常型进行期银屑病药物治疗进展[J].山东中医杂志,2006,25(1):67-70
[9]孙建方.银屑病免疫学发病机制研究进展[J].青岛大学医学院报,2001,37(1):1-2
[10]姜海燕,方栩.白介素在银屑病发病机制中的研究新进展[J].国外医学皮肤性病学分册,2003,29(5):288-290
[11]Kerkhof PCM van de,Gerriteen MJP,Dooren - Greeke RJ van,et al.What is new in the teatment of psoriasis[J].J Dermatol treat.1996,7:255.
[12]周海润,郑家燕.一些治疗银屑病药物的药理及临床研究[J].国外医学皮肤性病学分册,2001,27(2):67-70
[13]顾有守.银屑病的治疗现况[J].临床皮肤科杂志,2003,32(8):487-490
[14]高春芳,郑茂荣.银屑病治疗的选择策略[J].国外医学皮肤性病学分册.2001,(27)3:165-168
[15]楚瑞琦,王冬云,谭升顺.银屑病的系统给药治疗[J].中国皮肤性病学杂志,2003,17(5):347-349
[16]张雪梅.银屑病治疗进展[J].内蒙古民族大学学报(自然科学版).2004,(19)1:92-95
[17]虞瑞尧,薛文昌.环孢素A免疫疗法治疗银屑病[J].皮肤病与性病,1998,20(3):15-18
[18]陈洪铎.寻常型银屑病的生物制剂治疗[J].沈阳医学院学报.2004,6(3):125-127
[19]Detmar M.The role of VEGF and thrombospondins in skin angio- genesis[J]J Dermatol Sci.2000,24(1):78- 84
[20]Diaz BV,Lenoir MC,Ladoux A,et al.Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids[J].J B iol Chem,2000,275(1):642-650
[21]Bouis D,Kusumanto Y,Meijer C,et al.A review on pro and antiangiogenic factors as targets of clinical intervention[J].Pharmacol Res.2006,53:89-103
[22]张彩萍,崔盘根.银屑病微血管异常增生机制及治疗对策[J].国际皮肤性病学杂志.2006,32(1):23-25
[23]Dvorak HK,Brown LF,Detmar,et al.Vascular permeability factor/vascular endothelial growth factor,microvascular hyperpermeability,and angiogenesis.AJ Patho- l,1995,36:169-175
[24]Bhushan M,M claugh B,Weiss JB,et al.Level of endothelial cell stimulating angiogenesis factor and vascular endothelial growth facto r are elevated in psoriasis[J].B r J D erm atol,1999,141(6):1054-1060
[25]Xia YP,Li B,Hylton D,et al.Transgenic delivery of VEGF tomouse skin leads to an inflammatory condition resembling humanpsoriasis[J].Blood,2003,102:161-168.
[26]Carmelict P,Lampu G,Moon L,et al.Targeted deficiency or cytosolic truncation of theVE-cadherin gene in mice impairs VEGF2 mediated endothelial sur- vival and angiogenesis[J].Cell,1999,98(2):147-157
[27]朱凡,郑敏.血管内皮生长因子受体与银屑病血管异常的关系[J].浙江大学学报(医学版),2003,32(6):543-546
[28]高春芳,郑茂荣.角质形成细胞在银屑病发病机制中的研究进展[J].国外医学皮肤性病学分册,2000,26(4):216-219
[29]Creamer D,Sullivan D,Bicknell R,et al.Angiogenesis in psoriasis[J].Angiogenesi- s,2002,5:231-236
[30]朱帆,郑敏,鲍彰.银屑病皮损中VEGF受体的表达[J].中华皮肤科杂志,2003,36(7):365-367
[31]贺石林,王健,王净净.中医科研设计与统计学[M],第一版,湖南:湖南科学技术出版社,52
[32]吕世静、黄槐莲、袁汉尧.白茅根多糖对T淋巴细胞免疫调节效应的研究[J].中国新药杂志,2004,13(9):834-835
[33]单保思,张金艳,杜肖娜.白花蛇舌草的免疫学调节活性和抗肿瘤性[J].中国中西医结合 杂志,2001,21(5):370-374
[34]黄琪,周飞红,李东升.中医治则组方治疗银屑病作用机制的研究进展[J].中国麻风皮肤病杂志,2007,23(6):504-506
[1]姜海燕,方栩.白介素在银屑病发病机制中的研究新进展[J]国外医学皮肤性病学分册.2003,29(5):288-290
[2]于延,刘晓明,侯素春.凉血活血汤治疗寻常型银屑病临床观察及及对血清IL-8的影响[J]中国麻风皮肤病学杂志2005,21(9):712-714
[3]李伟凡,王萍,娄卫海.凉血活血汤治疗寻常型银屑病临床观察及肿瘤坏死因子和白细胞介素8水平检测[J]临床皮肤科杂志.2002,31(12):770-771
[4]陈红,王思平.复方青黛胶囊治疗寻常型银屑病的疗效观察及其对血清IL-2、IL-8的影响[J]中药材2004,27(11):885-886
[5]马学伟,刘巧格,刘亚欣,等.克银1号胶囊治疗进行期寻常型银屑病的临床研究[J]河北中医2003,2(8):567-569
[6]张晓红,瞿幸,牛福林,等.消银解毒饮对银屑病患者鳞屑白介素8的影响[J]中华皮肤科杂志2000,33(2):124
[7]杨志波,向亚萍,欧阳恒.银屑病患者口服竹黄颗粒剂前后血清白介素6和肿瘤坏死因子α水平的比较[J]中华皮肤科杂志2000,33(6):423
[8]郑敏.银屑病是细胞免疫介导性疾病[J]中华皮肤科杂志2002,35(2):85-87
[9]杨素梅,徐艳,杨柳竹,等.疏瘀清银汤对寻常型银屑病患者血管内皮生长因子的调节作用[J]现代中西医结合杂志2004,13(9):1176-1177
[10]石继海,鞠强,夏隆庆.银屑病发病机理的某些研究进展[J]国外医学皮肤性病学分册2002,28(3):148-150
[11]刘海杰,欧阳恒,杨志波,等.仙方消银片对寻常型银屑病患者血浆内皮素1及降盖素基因相关肽含量的研究[J]中国麻风皮肤病杂志2005,21(1):13-15
[12]周萌,陶林昌.理血消银汤治疗银屑病临床疗效及对血浆内皮素的影响[J]中国中西医结合杂志2005,25(10):929-931
[13]关杨,冀润利,李治劳.银屑宁胶囊对小鼠角质形成细胞增殖、分化及对血浆内皮素含量的影响[J]中国中西医结合皮肤性病学杂志2003,2(2):101-103
[14]杨志波,欧阳恒,许斌,等.竹黄颗粒剂Ⅱ号对银屑病患者β-内啡肽的影响[J]中国中西医结合皮肤性病学杂志2003,2(3):166-167
[15]吴胜利,许能,陈建明,等.解毒化淤汤治疗银屑病的临床和实验研究[J]中华皮肤科杂志2004,37(3:)133-134
[16]孙丽蕴,邓丙戍,王禾,等.凉血活血胶囊对皮肤角质形成细胞凋亡的研究[J]中华皮肤科杂志2003,36(10):583-585
[17]吴晓霞,周武庆,禤国维.愈银方含药血清对角质形成细胞增殖与凋亡的影响[J]中国中医药信息杂志2003,10(8):35-37
[18]吴晓霞,贾红声.愈银方治疗寻常型银屑病的实验研究[J]河北中医2003,25(7):559-560
[19]许能,吴胜利,马绍尧.凉血解毒中药治疗银屑病的实验研究[J]上海中医药大学学报2004,18(2)
[20]杨志波,欧阳恒,谭诚,等.竹黄颗粒剂对角质形成细胞增殖影响的实验研究[J]中国皮肤性病学杂志2000,14(5):309-311
[21]邱实,谭升顺,孙治平,等.活血散瘀消银汤治疗寻常型银屑病血瘀证的临床研究[J]中药材2005,28(5):442-444
[22]肖青林,司本辉,吴康智,等.不同剂量丹参治疗银屑病患者后血液流变学改变[J]中华皮肤科杂志2000,3(6):414-415
[23]张志明.清热凉血汤治疗银屑病进行期临床及实验室观察[J]中国中西医结合皮肤性病学杂志2005,4(1):12-14
[24]周萌,陈会茹,陶林昌.血府逐瘀汤治疗寻常型银屑病30例临床观察[J]北京中医药大 学学报2005,12(5):14-16
[25]张凡.解毒散瘀汤治疗血瘀型银屑病对血脂、载脂蛋白、血液流变学的影响[J]中国中西医结合皮肤性病学杂志2004,3(3)154-155
[2]赵辩.临床皮肤病学[M],第3版,南京:江苏科学技术出版社,759
[3]陈积愫,郑敏.银屑病与血管生成因子[J].国外医学皮肤性病学分册,2000,26(1):13-16
[4]Jens Gille,Kerstin Reisinger,Bindhu Westphal-Varghese,et al.Decreased mRNA Stability as a Mechanism of Glucocorticoid-Mediated Inhibition of Vascular Endoth- elial Growth Factor Gene Expression by Cultured Keratinocytes[J].The journal of investigative dermatology.2001,117(6):1851-1857
[5]林熙然.隋代到清代中医医籍中有关银屑病的资料综述[J].中国中西医结合皮肤性病学杂志,2002,1(1):60-63
[6]孙捷,张虹亚.中医药治疗银屑病的研究进展[J].甘肃中医.2007,20(7):95-97
[7]北京中医医院.赵炳南临床经验集[M].北京:人民卫生出社,1997:227
[8]杜锡贤,范玉.寻常型进行期银屑病药物治疗进展[J].山东中医杂志,2006,25(1):67-70
[9]孙建方.银屑病免疫学发病机制研究进展[J].青岛大学医学院报,2001,37(1):1-2
[10]姜海燕,方栩.白介素在银屑病发病机制中的研究新进展[J].国外医学皮肤性病学分册,2003,29(5):288-290
[11]Kerkhof PCM van de,Gerriteen MJP,Dooren - Greeke RJ van,et al.What is new in the teatment of psoriasis[J].J Dermatol treat.1996,7:255.
[12]周海润,郑家燕.一些治疗银屑病药物的药理及临床研究[J].国外医学皮肤性病学分册,2001,27(2):67-70
[13]顾有守.银屑病的治疗现况[J].临床皮肤科杂志,2003,32(8):487-490
[14]高春芳,郑茂荣.银屑病治疗的选择策略[J].国外医学皮肤性病学分册.2001,(27)3:165-168
[15]楚瑞琦,王冬云,谭升顺.银屑病的系统给药治疗[J].中国皮肤性病学杂志,2003,17(5):347-349
[16]张雪梅.银屑病治疗进展[J].内蒙古民族大学学报(自然科学版).2004,(19)1:92-95
[17]虞瑞尧,薛文昌.环孢素A免疫疗法治疗银屑病[J].皮肤病与性病,1998,20(3):15-18
[18]陈洪铎.寻常型银屑病的生物制剂治疗[J].沈阳医学院学报.2004,6(3):125-127
[19]Detmar M.The role of VEGF and thrombospondins in skin angio- genesis[J]J Dermatol Sci.2000,24(1):78- 84
[20]Diaz BV,Lenoir MC,Ladoux A,et al.Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids[J].J B iol Chem,2000,275(1):642-650
[21]Bouis D,Kusumanto Y,Meijer C,et al.A review on pro and antiangiogenic factors as targets of clinical intervention[J].Pharmacol Res.2006,53:89-103
[22]张彩萍,崔盘根.银屑病微血管异常增生机制及治疗对策[J].国际皮肤性病学杂志.2006,32(1):23-25
[23]Dvorak HK,Brown LF,Detmar,et al.Vascular permeability factor/vascular endothelial growth factor,microvascular hyperpermeability,and angiogenesis.AJ Patho- l,1995,36:169-175
[24]Bhushan M,M claugh B,Weiss JB,et al.Level of endothelial cell stimulating angiogenesis factor and vascular endothelial growth facto r are elevated in psoriasis[J].B r J D erm atol,1999,141(6):1054-1060
[25]Xia YP,Li B,Hylton D,et al.Transgenic delivery of VEGF tomouse skin leads to an inflammatory condition resembling humanpsoriasis[J].Blood,2003,102:161-168.
[26]Carmelict P,Lampu G,Moon L,et al.Targeted deficiency or cytosolic truncation of theVE-cadherin gene in mice impairs VEGF2 mediated endothelial sur- vival and angiogenesis[J].Cell,1999,98(2):147-157
[27]朱凡,郑敏.血管内皮生长因子受体与银屑病血管异常的关系[J].浙江大学学报(医学版),2003,32(6):543-546
[28]高春芳,郑茂荣.角质形成细胞在银屑病发病机制中的研究进展[J].国外医学皮肤性病学分册,2000,26(4):216-219
[29]Creamer D,Sullivan D,Bicknell R,et al.Angiogenesis in psoriasis[J].Angiogenesi- s,2002,5:231-236
[30]朱帆,郑敏,鲍彰.银屑病皮损中VEGF受体的表达[J].中华皮肤科杂志,2003,36(7):365-367
[31]贺石林,王健,王净净.中医科研设计与统计学[M],第一版,湖南:湖南科学技术出版社,52
[32]吕世静、黄槐莲、袁汉尧.白茅根多糖对T淋巴细胞免疫调节效应的研究[J].中国新药杂志,2004,13(9):834-835
[33]单保思,张金艳,杜肖娜.白花蛇舌草的免疫学调节活性和抗肿瘤性[J].中国中西医结合 杂志,2001,21(5):370-374
[34]黄琪,周飞红,李东升.中医治则组方治疗银屑病作用机制的研究进展[J].中国麻风皮肤病杂志,2007,23(6):504-506
[1]姜海燕,方栩.白介素在银屑病发病机制中的研究新进展[J]国外医学皮肤性病学分册.2003,29(5):288-290
[2]于延,刘晓明,侯素春.凉血活血汤治疗寻常型银屑病临床观察及及对血清IL-8的影响[J]中国麻风皮肤病学杂志2005,21(9):712-714
[3]李伟凡,王萍,娄卫海.凉血活血汤治疗寻常型银屑病临床观察及肿瘤坏死因子和白细胞介素8水平检测[J]临床皮肤科杂志.2002,31(12):770-771
[4]陈红,王思平.复方青黛胶囊治疗寻常型银屑病的疗效观察及其对血清IL-2、IL-8的影响[J]中药材2004,27(11):885-886
[5]马学伟,刘巧格,刘亚欣,等.克银1号胶囊治疗进行期寻常型银屑病的临床研究[J]河北中医2003,2(8):567-569
[6]张晓红,瞿幸,牛福林,等.消银解毒饮对银屑病患者鳞屑白介素8的影响[J]中华皮肤科杂志2000,33(2):124
[7]杨志波,向亚萍,欧阳恒.银屑病患者口服竹黄颗粒剂前后血清白介素6和肿瘤坏死因子α水平的比较[J]中华皮肤科杂志2000,33(6):423
[8]郑敏.银屑病是细胞免疫介导性疾病[J]中华皮肤科杂志2002,35(2):85-87
[9]杨素梅,徐艳,杨柳竹,等.疏瘀清银汤对寻常型银屑病患者血管内皮生长因子的调节作用[J]现代中西医结合杂志2004,13(9):1176-1177
[10]石继海,鞠强,夏隆庆.银屑病发病机理的某些研究进展[J]国外医学皮肤性病学分册2002,28(3):148-150
[11]刘海杰,欧阳恒,杨志波,等.仙方消银片对寻常型银屑病患者血浆内皮素1及降盖素基因相关肽含量的研究[J]中国麻风皮肤病杂志2005,21(1):13-15
[12]周萌,陶林昌.理血消银汤治疗银屑病临床疗效及对血浆内皮素的影响[J]中国中西医结合杂志2005,25(10):929-931
[13]关杨,冀润利,李治劳.银屑宁胶囊对小鼠角质形成细胞增殖、分化及对血浆内皮素含量的影响[J]中国中西医结合皮肤性病学杂志2003,2(2):101-103
[14]杨志波,欧阳恒,许斌,等.竹黄颗粒剂Ⅱ号对银屑病患者β-内啡肽的影响[J]中国中西医结合皮肤性病学杂志2003,2(3):166-167
[15]吴胜利,许能,陈建明,等.解毒化淤汤治疗银屑病的临床和实验研究[J]中华皮肤科杂志2004,37(3:)133-134
[16]孙丽蕴,邓丙戍,王禾,等.凉血活血胶囊对皮肤角质形成细胞凋亡的研究[J]中华皮肤科杂志2003,36(10):583-585
[17]吴晓霞,周武庆,禤国维.愈银方含药血清对角质形成细胞增殖与凋亡的影响[J]中国中医药信息杂志2003,10(8):35-37
[18]吴晓霞,贾红声.愈银方治疗寻常型银屑病的实验研究[J]河北中医2003,25(7):559-560
[19]许能,吴胜利,马绍尧.凉血解毒中药治疗银屑病的实验研究[J]上海中医药大学学报2004,18(2)
[20]杨志波,欧阳恒,谭诚,等.竹黄颗粒剂对角质形成细胞增殖影响的实验研究[J]中国皮肤性病学杂志2000,14(5):309-311
[21]邱实,谭升顺,孙治平,等.活血散瘀消银汤治疗寻常型银屑病血瘀证的临床研究[J]中药材2005,28(5):442-444
[22]肖青林,司本辉,吴康智,等.不同剂量丹参治疗银屑病患者后血液流变学改变[J]中华皮肤科杂志2000,3(6):414-415
[23]张志明.清热凉血汤治疗银屑病进行期临床及实验室观察[J]中国中西医结合皮肤性病学杂志2005,4(1):12-14
[24]周萌,陈会茹,陶林昌.血府逐瘀汤治疗寻常型银屑病30例临床观察[J]北京中医药大 学学报2005,12(5):14-16
[25]张凡.解毒散瘀汤治疗血瘀型银屑病对血脂、载脂蛋白、血液流变学的影响[J]中国中西医结合皮肤性病学杂志2004,3(3)154-155